newsfilter
← Latest News
GlobeNewswire·

Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets

Lead DMT-assisted therapy candidate SPL026's clinical development program strengthened with the addition of two clinical trials planned for 2022 SPL028, a deuterated DMT candidate with Composition of Matter patent protection in the UK, moves towards P